linjc16/ctgov huggingface dataset:
Prevalance of Cesarean Section Niche in Patients With Abnormal Uterine Bleeding

Study Overview
=================
Brief Summary
-----------------
Prevalance of Cesarean section niche in patients with abnormal uterine bleeding

Official Title
-----------------
Prevalance of Cesarean Section Niche in Patients With Abnormal Uterine Bleeding

Conditions
-----------------
Cesarean Section Niche and Abnormal Uterine Bleeding

Intervention / Treatment
-----------------
* Other: By TVS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 20-40 years old. Non pregnant women. Previous cesarean section (one or more). Presence of abnormal uterine bleeding Exclusion Criteria: Virgins Pregnant women. Patients with vaginal delivery. Patients with uterine bleeding with known cause.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cesarean section niche and patients with abnormal uterine bleeding<br>Observation by Tvs | Other: By TVS<br>* Uses of TVS to diagnosis of Cesarean section niche in patients with abnormal uterine bleeding<br>|
| Abnormal uterine bleeding in patients without Cesarean section niche<br>Observation by Tvs | Other: By TVS<br>* Uses of TVS to diagnosis of Cesarean section niche in patients with abnormal uterine bleeding<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cesarean section niche in patients with abnormal uterine bleeding | To study relationship between the niche and the abnormal uterine bleeding | 6 months |
The Role of Melatonin in the Regulation of Blood Coagulation

Study Overview
=================
Brief Summary
-----------------
The main aim is to examine the influence of daylight and melatonin on the temporal variations of hemostatic factors with key roles in the hemostatic process and its regulation. Particular emphasis will be on exploring the role of melatonin in hemostasis by comparing subjects with tetraplegia with able-bodied control subjects.

Official Title
-----------------
The Role of Melatonin in the Regulation of Blood Coagulation

Conditions
-----------------
Spinal Cord Injured, Tetraplegia

Intervention / Treatment
-----------------
* Drug: Melatonin (Circadin)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Intervention group: A diagnosis of tetraplegia for at least 2 years, and otherwise healthy. Must not use drugs permanently (except anti-spasmolytics). Must be able to swallow tablets. Must give written consent to participate. Control group: Must be healthy. Must not use drugs permanently. Must give written consent to participate. Exclusion Criteria: Both groups: Those with acute or chronic co-morbidity. Unable to cooperate. Not provided written consent to participate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Sleep only<br>Placebo given at night to tetraplegic individuals before going to sleep, | Drug: Melatonin (Circadin)<br> <br> |
| Active Comparator: Melatonin<br>Melatonin given at night to tetraplegic individuals before going to sleep. | Drug: Melatonin (Circadin)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Circadian variation of hemostatic factors |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Circadian variation, hemostasis, melatonin, tetraplegia
Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

Study Overview
=================
Brief Summary
-----------------
To evaluate the effects of VSL#3 on symptoms associated with diarrhea predominant IBS

Detailed Description
-----------------
The study will evaluate 2 doses of VSL#3 and placebo over a 4 week period in patients presenting with diarrhea predominant IBS symptoms.

Official Title
-----------------
A Randomized, Multi-center, Double-blind, Placebo Controlled, Dose Ranging Study With VSL#3 in Diarrhea Predominant IBS Patients

Conditions
-----------------
IBS

Intervention / Treatment
-----------------
* Drug: VSL#3


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IBS diarrhea Exclusion Criteria: < 18 years of age Pregnancy/breast feeding concomitant medications to reduce bowel function

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: VSL#3|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global improvement in IBS symptoms |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of bowel movements |  |  | 
| Changes in abdominal pain |  |  | 
| Changes in bloating |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IBS, Functional bowel disorder, Diarrhea, probiotic
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke

Study Overview
=================
Brief Summary
-----------------
This study will consist of 2 phases. Phase 1 will be a one day crossover study to see the effects of study product on a smoker's desire to smoke, measured by changes in scores on questionnaires given over time. Phase 2 will be a two-week extension, in which subjects will self-administer the study product and visit the study site for assessment of desire to smoke and collection of samples for the evaluation of smoking-related biomarkers.

Official Title
-----------------
A Single Center, Single-Blind, Randomized, Crossover Pilot Study to Evaluate the Safety and Effects of Anatabloc™, a Dietary Supplement, in Reducing the Urge to Smoke in Daily Smokers Followed by an Open-Label Extension

Conditions
-----------------
Tobacco Use Disorder, Tobacco Dependence, Smoking

Intervention / Treatment
-----------------
* Dietary Supplement: Anatabloc(TM)
* Dietary Supplement: CigRx(R)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy adult smokers using at least 1 pack of cigarettes per day, for at least 5 years Exclusion Criteria: allergy to study product components

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 72 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Anatabloc(TM)<br>dissolvable bit containing dietary ingredients, binders, fillers, and flavors | Dietary Supplement: Anatabloc(TM)<br>* one dissolvable bit, one time, after a period of abstinence from smoking<br>|
| Active Comparator: CigRx(R)<br>dissolvable bit containing dietary ingredients, binders, fillers, and flavors | Dietary Supplement: CigRx(R)<br>* one dissolvable bit, one time, after a period of abstinence from smoking<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| effect on subject's craving to smoke | craving is assessed by changes in questionnaire answers over time | 5 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adverse events related to study product | collection of information on adverse events related to study product | 5 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dietary supplement, nutraceutical
Comparing Patient Satisfaction of the Abdomen After DIEAP Procedure and Conventional Abdominoplasty

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to specifically compare the long term patient satisfaction of the abdomen after DIEAP flap procedure with conventional abdominoplasty.

Detailed Description
-----------------
34 patients reconstructed with a DIEAP flap (DIEAP group) and 30 patients who had undergone a conventional abdominoplasty (AP group) were asked to complete two study-specific questionnaires. One questionnaire covered general and specific aspects concerning abdominal outcomes and morbidity. The other covered general outcomes such as satisfaction with surgery and change of body image, self-confidence, social and intimate relations. In addition, all patients performed an abdominal muscle function test.

Official Title
-----------------
Comparing Patient Satisfaction of the Abdomen After DIEAP Procedure and Conventional Abdominoplasty

Conditions
-----------------
Donor Site Complication, Satisfaction, Personal, Breast Cancer

Intervention / Treatment
-----------------
* Behavioral: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: unilateral DIEAP flap, abdominoplasty Exclusion Criteria: bilateral DIEAP flap, progressive cancer disease

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| DIEAP group<br>Patients who had undergone DIEAP flap breast reconstruction | Behavioral: Questionnaire<br>* Two study-specific questionnaires<br>|
| AP group<br>Patients who had undergone conventional abdominoplasty | Behavioral: Questionnaire<br>* Two study-specific questionnaires<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparing patient satisfaction of the abdomen after DIEAP procedure and conventional abdominoplasty | The purpose of this study was to specifically compare the long term patient satisfaction of the abdomen after DIEAP flap procedure with conventional abdominoplasty. | 2001 to 2004. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast reconstruction; abdominoplasty; patient satisfaction
Effect of Per-cutaneous Nephrosotomy Drainage on Radioisotope Imaging of Hydronephrotic Kidneys

Study Overview
=================
Brief Summary
-----------------
Hydronephrosis describes a condition of urine-filled dilation of the collecting system. Normally, urine flows through the urinary tract with minimal or low pressure. If the build-up of excess fluid in the urinary collecting system continues, there will be an increase in pressure and atrophy of renal cortex. If hydronephrosis is left untreated for a long time, renal damage with permanent loss of function occurs

Official Title
-----------------
Effect of Per-cutaneous Nephrosotomy Drainage on Radioisotope Imaging of Hydronephrotic Kidneys

Conditions
-----------------
Hydronephrosis

Intervention / Treatment
-----------------
* Procedure: percutaneous nephrostomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) Patients for whom a percutaneous nephrostomy is indicated provided that the hydronephrosis is advanced ( parenchymal thickness not more than 5 mm ) 2) Patients for whom a nephrectomy is planned for a seemingly poorly functioning kidney along with either Exclusion Criteria: Target kidney is the only functioning or better functioning kidney or otherwise substantially contributing to the total renal function, so nephrectomy is not likely. Emergency cases where the general condition of the patient cannot withstand the logistics of undergoing a radioisotope study eg Malignancy in the target kidney Patients unlikely to undergo a nephrectomy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group<br>Patients will be recruited from out-patient clinics and in-patient sectors of Assiut Urology and Nephrology hospital | Procedure: percutaneous nephrostomy<br>* The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The rate of increase in glomerular filtration rate after intervention | the radioisotope measurement of glomerular filtration rate will be done before and after insertion of percutaneous nephrostomy tube | 3 weeks |
Practice of Mechanical Ventilation in Patients With Severe Brain Injury in China

Study Overview
=================
Brief Summary
-----------------
The mechanical ventilation strategy has changed over years worldwide. Several international researches have been conducted to study the association of the use of mechanical ventilation with clinical outcomes. In this prospective, multicenter, cross-sectional survey, the practice of mechanical ventilation among patients with severe brain injury will be investigated in 70 intensive care units in China.

Official Title
-----------------
A Survey on the Practice of Mechanical Ventilation Among Patients With Severe Brain Injury in China: a Prospective Observational Study

Conditions
-----------------
Respiration, Artificial

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: older than 18 years with severe brain injury (including severe traumatic brain injury, ischemic stroke, subarachnoid hemorrhage, spontaneous intracerebral hemorrhage, hypoxic-ischemic encephalopathy, intracranial tumor, intracranial infection and idiopathic epilepsy) mechanical ventilated for at least 24 hours before the time of on-spot survey Exclusion Criteria: undergoing a spontaneous breathing trial (SBT) at the time of on-spot survey underwent at least once SBT in the preceding 24 hours before time of on-spot survey enrolled in another trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients receiving control and assist mode of mechanical ventilation | Control mode is defined as volume or pressure control ventilation. Assist mode is defined as synchronized intermittent mandatory ventilation and pressure support ventilation. | During 1 hour of on-spot survey | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The settings of tidal volume, inspiratory pressure, and positive end-expiratory pressure in enrolled patients |  | During 1 hour of on-spot survey | 
| Duration of mechanical ventilation |  | 60 days after on-spot survey | 
| Number of patients liberated from mechanical ventilation |  | 60 days after on-spot survey | 
| Neurological outcome by Glasgow Outcome Scale |  | 60 days after on-spot survey | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mechanical ventilation, epidemiology, intensive care unit, national survey
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole

Study Overview
=================
Brief Summary
-----------------
This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.

Official Title
-----------------
An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628)

Conditions
-----------------
Restless Legs Syndrome

Intervention / Treatment
-----------------
* Drug: ropinirole dosing for up to 28 days


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Patients and subjects between 18-79 years old. End stage renal patients who are consistently receiving dialysis for a minimum of 3.5 hours, three times per week, with hemodialysis blood flow rates of >200mL/min may be eligible to enter the study. Patients must also have systolic blood pressure 100-190mmHg and diastolic blood pressure <120mmHg. Healthy subjects must have systolic blood pressure 100-150mmHg. Exclusion: Female subjects who are pregnant and/or breast-feeding must not participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ropinirole dosing for up to 28 days|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SK&F-104557 and SK&F-89124 blood levels over 24 hours at Weeks 1 & 3 for all subjects. |  |  | 
| SK&F-104557 and SK&F-89124 blood levels at beginning, middle, & end of hemodialysis period when on dialysis & off dialysis in patients. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ECG: every other visit |  |  | 
| Vital Signs: Each visit |  |  | 
| Adverse Events: each visit |  |  | 
| Clinical laboratory: every other visit |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
end stage renal impairment, tolerability, ropinirole, pharmacokinetics, hemodialysis
Smartphone-based Ophthalmoscopy

Study Overview
=================
Brief Summary
-----------------
A subset of 120 diabetic patients underwent dilated examination and smartphone ophthalmoscopy. The smartphone was equipped with a compact add-on that filtered and delivered the smartphone's LED light coaxially to the camera, allowing a clear and convenient view of the retina.

Official Title
-----------------
Comparison of Smartphone-based Ophthalmoscopy Versus Dilated Ophthalmic Examination for Diabetic and Nondiabetic Eye Disease

Conditions
-----------------
Diabetic Retinopathy Grading

Intervention / Treatment
-----------------
* Other: Ophthalmoscopy conducted using a smartphone equipped with a compact addon
* Device: Smartphone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: type 1 or 2 diabetes ability to provide written informed consent Exclusion Criteria: significant optic media opacities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Diabet patients<br>Smartphone ophthalmoscopy followed by traditional slit-lamp dilated ophthalmoscopy | Other: Ophthalmoscopy conducted using a smartphone equipped with a compact addon<br> <br> Device: Smartphone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diabetic retinopathy grading | The grading was performed according to the Early Treatment Diabetic Retinopathy Study (ETDRS) diabetic retinopathy classification. Grade 0: no diabetic retinopathy Grade 1: mild non-proliferative diabetic retinopathy Grade 2: average non-proliferative diabetic retinopathy Grade 3: severe non-proliferative diabetic retinopathy Grade 4: proliferative diabetic retinopathy | The same day as dilated ophthalmic examination |